Sartorius Stedim Biotech (SSB) is launching a new initiative for “end-to-end” security across the entire supply chain spectrum. The supply-chain security initiative will cover three elements: membership in the RX-360 Consortium, implementation of global guidelines for wooden pallets, and tamper-evident packaging.
By David Vaczek, Senior Editor
With buy in from all pharma supply chain sectors, the RxTEC Act provides a model for automated lot-level tracking.
With the RxTEC Act, pharmaceutical supply chain members are proposing a phased-in approach to track-and-trace with a federal law imposing uniform requirements on all states.
Pharmaceutical and biological product shippers will be able to track the condition and status of their cargo across the entire Delta Air Lines and Delta Connection fleet, which operates more than 5000 daily flights to more than 340 destinations, 61 countries, and six continents. Delta Air Lines has received FAA approval to use SENTRY 400 FlightSafe devices from OnAsset Intelligence (www.onasset.com) on all of its main-line and connecting flights, giving shippers product visibility throughout aviation distribution.
One of the most common mistakes in preparing products for the cold chain is using the wrong shipping profile, reports Gary M. Hutchinson, formerly director of global transportation at Amgen. “As a result, companies could be over designing or under designing their packaging systems.” Such a mistake means that companies could be spending far too much on their systems—or protecting their products far too little.
A group of health care organizations have written a letter to Jeff Zients, Acting Director of the Office of Management and Budget (OMB), asking for the release of FDA's proposed rule on Unique Device Identifiers (UDIs). According to FDA, Section 226 of the Food and Drug Administration Amendments Act of 2007 (FDAAA) directs FDA to issue regulations establishing a UDI system for medical devices. This system is intended to improve the identification of devices throughout distribution and use.
The associations that submitted the letter are:
The pharmaceutical industry is no longer defined—or confined—by borders. Manufacturers are sourcing ingredients, materials, finished products, and contract packaging and manufacturing from around the world, and most are seeking to serve patients in multiple markets. The resulting supply chain is a complex one.
“Things are changing,” says Brian Johnson, senior director, supply-chain security, Pfizer Inc. “Markets are expanding, and where we are sourcing materials and manufacturing is changing.”
In a press release issued by Endo Pharmaceuticals, the company expressed concerns that the halting of production at Novartis Consumer Health’s manufacturing facility in Lincoln, NE—coming on the heels of production and packaging problems—will lead to short-term supply constraints for its pharmaceutical offerings.
TÜV Rheinland Industrial Solutions has introduced a new emergency rapid response service called Containment Emergency Response Team (C.E.R.T.). Developed to minimize OEM production disruptions when out-of-specification products have entered the supply chain, C.E.R.T. is made up of certified inspectors who can respond nationally and internationally to suspected quality issues throughout the supply chain.